Switzerland-based Roche has agreed to provide HIV-1 viral load and early infant diagnostic technologies for the Global Fund.
Under the collaboration, Roche will provide HIV-1 tests with dual-target design to simultaneously amplify and detect two separate regions of the HIV-1 genome that are not subject to selective drug pressure.
Roche Molecular Diagnostics head Paul Brown said: "We are proud to be chosen as a supplier for the Global Fund and to continue to provide reliable HIV-1 diagnostics where they are needed most.
"Leveraging our vast number of systems already installed around the world and continuing to work with organizations such as the Global Fund, we expand our commitment to healthcare solutions which make a real difference in those regions most impacted by HIV."
The dual-target HIV-1 qualitative test, v2.0, works with both plasma and dried blood spot (DBS) collection cards for early infant diagnostics.
It is said to avoid the need of refrigeration and decreases the volume of blood required, as well as makes sample collection and transportation easy, including from the smallest infant in the most rural area.
In 2014, Roche announced the Global Access Program in collaboration with the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Clinton Health Access Initiative (CHAI), the President’s Emergency Plan For AIDS Relief (PEPFAR) and the Global Fund to fight AIDS, TB & Malaria.